Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $14

RBC Capital analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $15 to $14.
byBenzinga Newsdesk
May 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $15 to $14.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0